ATE502641T1 - Kombination aus azd2171 und pemetrexed - Google Patents

Kombination aus azd2171 und pemetrexed

Info

Publication number
ATE502641T1
ATE502641T1 AT06820574T AT06820574T ATE502641T1 AT E502641 T1 ATE502641 T1 AT E502641T1 AT 06820574 T AT06820574 T AT 06820574T AT 06820574 T AT06820574 T AT 06820574T AT E502641 T1 ATE502641 T1 AT E502641T1
Authority
AT
Austria
Prior art keywords
azd2171
pemetrexed
human
combination
antiangiogenic
Prior art date
Application number
AT06820574T
Other languages
English (en)
Inventor
Stephen Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0526132A external-priority patent/GB0526132D0/en
Priority claimed from GB0610708A external-priority patent/GB0610708D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE502641T1 publication Critical patent/ATE502641T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Ink Jet (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06820574T 2005-12-22 2006-12-19 Kombination aus azd2171 und pemetrexed ATE502641T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526132A GB0526132D0 (en) 2005-12-22 2005-12-22 Combination Therapy
GB0610708A GB0610708D0 (en) 2006-05-31 2006-05-31 Combination therapy
PCT/GB2006/004768 WO2007071970A2 (en) 2005-12-22 2006-12-19 Combination of azd2171 and pemetrexed

Publications (1)

Publication Number Publication Date
ATE502641T1 true ATE502641T1 (de) 2011-04-15

Family

ID=37964934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06820574T ATE502641T1 (de) 2005-12-22 2006-12-19 Kombination aus azd2171 und pemetrexed

Country Status (19)

Country Link
US (1) US20080306094A1 (de)
EP (1) EP1965801B1 (de)
JP (1) JP2009520787A (de)
KR (1) KR20080077678A (de)
AT (1) ATE502641T1 (de)
AU (1) AU2006328201B2 (de)
BR (1) BRPI0620118A2 (de)
CA (1) CA2631676A1 (de)
CY (1) CY1111482T1 (de)
DE (1) DE602006020919D1 (de)
DK (1) DK1965801T3 (de)
HR (1) HRP20110365T1 (de)
IL (1) IL191797A0 (de)
NO (1) NO20082566L (de)
NZ (1) NZ568812A (de)
PL (1) PL1965801T3 (de)
PT (1) PT1965801E (de)
SI (1) SI1965801T1 (de)
WO (1) WO2007071970A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US20080113039A1 (en) * 2004-03-23 2008-05-15 Stephen Robert Wedge Combination Therapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2007003933A2 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
DE602006020621D1 (de) * 2005-12-22 2011-04-21 Astrazeneca Ab Kombination von zd6474 und pemetrexed
US20090221615A1 (en) * 2008-02-29 2009-09-03 Guru Reddy Combination anti-cancer agents
CA2789895C (en) 2010-03-08 2019-04-09 Spectrum Pharmaceuticals, Inc. Thioxanthone-based autophagy inhibitor therapies to treat cancer
WO2017020048A1 (en) * 2015-07-30 2017-02-02 Expression Pathology, Inc. QUANTIFYING FR-α AND GART PROTEINS FOR OPTIMAL CANCER THERAPY

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518341A (ja) * 1998-06-15 2002-06-25 アーチ・デヴェロップメント・コーポレイション 放射線療法と抗血管形成因子の組み合わせ
BRPI0017548B8 (pt) * 1999-02-10 2023-05-02 Astrazeneca Ab Composto
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
US20080113039A1 (en) * 2004-03-23 2008-05-15 Stephen Robert Wedge Combination Therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
BRPI0511065A (pt) * 2004-06-04 2007-12-26 Pfizer Prod Inc método para tratar crescimento de célula anormal
KR20070073813A (ko) * 2004-09-27 2007-07-10 아스트라제네카 아베 Ａｚｄ2171 및 이마티닙을 포함하는 암의 병합 요법
WO2007003933A2 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
EP2518083A3 (de) * 2005-12-15 2012-12-05 Medimmune Limited Kombination eines Angiopoetin-2-Antagonisten und eines VEGF-A, KDR- und/oder FLTL-Antagonisten zur Behandlung von Krebs
DE602006020621D1 (de) * 2005-12-22 2011-04-21 Astrazeneca Ab Kombination von zd6474 und pemetrexed

Also Published As

Publication number Publication date
PT1965801E (pt) 2011-05-25
CA2631676A1 (en) 2007-06-28
DE602006020919D1 (de) 2011-05-05
IL191797A0 (en) 2008-12-29
AU2006328201B2 (en) 2010-08-19
KR20080077678A (ko) 2008-08-25
JP2009520787A (ja) 2009-05-28
NZ568812A (en) 2011-09-30
DK1965801T3 (da) 2011-06-14
US20080306094A1 (en) 2008-12-11
BRPI0620118A2 (pt) 2011-11-01
WO2007071970A2 (en) 2007-06-28
EP1965801A2 (de) 2008-09-10
EP1965801B1 (de) 2011-03-23
AU2006328201A1 (en) 2007-06-28
SI1965801T1 (sl) 2011-06-30
HK1123976A1 (en) 2009-07-03
WO2007071970A3 (en) 2007-08-09
NO20082566L (no) 2008-07-31
PL1965801T3 (pl) 2011-07-29
CY1111482T1 (el) 2015-08-05
HRP20110365T1 (hr) 2011-06-30

Similar Documents

Publication Publication Date Title
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
PL1653964T3 (pl) Skojarzone leczenie raka obejmujące AZD2171 i ZD1839
NO20064755L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1965801

Country of ref document: EP